In the previous report, when ovarian cancer patients with various AGP concentrations were treated with intravenous PTX modulating its pharmacokinetics by clindamycin binding to AGP, their toxicity was not increased [37]. The gene discussed is ATP5MK; the disease is ovarian cancer.